This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 167 entries.
Botanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors. Click here to view ASX Release.
Health Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors. Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners […]
Video is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.
Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™. Pre-register: Click here
To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar onTuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update oncommercial launch plans and market insights for Sofdra™. Registration to follow.
Quarterly Activity Report and 4C Quarterly Cash Flow Report released. At quarter end, Botanix held $79.31 million cash with no debt (other than typical trade creditors), which will fund operations as it ramps up manufacturing and sales activity of its Sofdra product. View Report.
Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe View Report.
Euroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target. View Report.
Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement. View ASX release.
